Global Regenerative Therapies Market Will Reach US$ 18,429.8 Mn by 2022: Persistence Market Research
Summary
Other trends driving the market growth include industry maturation, advancements in technology, and increasing demand for long-term results and shorter-time therapeutic procedures by patients.Moreover, high gestation period and time-to-market due to lengthy clinical trials, a large number of product recall within a short span post-approval, and lack of financial-backing by smaller firms are among the major factors hampering the growth of regenerative therapies market currently.Currently, hospitals are the most preferred option for patients globally.On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia Pacific & Japan, and the MEA regions.Rising per capita healthcare expenditure and contribution to GDP, increasing funding & government support for the development of regenerative therapies, as well as surge in incidences of chronic diseases are major factors driving the growth of the global regenerative therapies market currently.Other trends driving the market growth include industry maturation, advancements in technology, and increasing demand for long-term results and shorter-time therapeutic procedures by patients.Moreover, high gestation period and time-to-market due to lengthy clinical trials, a large number of product recall within a short span post-approval, and lack of financial-backing by smaller firms are among the major factors hampering the growth of regenerative therapies market currently.This report assesses trends driving each market segment and offers analysis and insights about the potential of regenerative therapies in specific regions.In terms of value, North America is estimated to be the dominant market, expanding at a CAGR of 19.7% over the forecast period.View Detail Report With TOC: http://www.persistencemarketresearch.com/market-research/regenerative-therapies-market.aspSome key companies covered in this report include Acelity L.P. Inc., Mesoblast Ltd., Nuo Therapeutics, Inc. (Cytomedix), Astellas Pharma US, Inc., Organovo Holdings Inc., Orgenesis Inc., Sanofi, Athersys, Inc., Shire Pharmaceuticals Limited, and Cytori Therapeutics Inc.